MYCN amplifications [5, 6] and activating ALK mutations or amplifications [7–10] define, among other molecular aberrations, patient subgroups with highly aggressive and frequently therapy-resistant neuroblastomas. This evidence concerns the gene MYCN and neuroblastoma.